Evrofarma (Greece) Top Management

Evrofarma Management Team Effectiveness

Evrofarma's management efficiency ratios could be used to measure how well Evrofarma manages its routine affairs as well as how well it operates its assets and liabilities. Evrofarma SA retains a total of 13.67 Million outstanding shares. Evrofarma SA shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 76.0 percent of Evrofarma SA outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity. Some institutional investors establish a significant position in stocks such as Evrofarma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Evrofarma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Evrofarma Workforce Comparison

The company has Profit Margin (PM) of (0.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average.

Evrofarma SA Benchmark Summation

Evrofarma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Evrofarma SA often depends on how effective the management is. Evrofarma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evrofarma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evrofarma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Evrofarma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Evrofarma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Evrofarma's management manipulating its earnings.

When running Evrofarma's price analysis, check to measure Evrofarma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evrofarma is operating at the current time. Most of Evrofarma's value examination focuses on studying past and present price action to predict the probability of Evrofarma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evrofarma's price. Additionally, you may evaluate how the addition of Evrofarma to your portfolios can decrease your overall portfolio volatility.